Volume 17, Number 3—March 2011
Research
Targeted Drug-Resistance Testing Strategy for Multidrug-Resistant Tuberculosis Detection, Lima, Peru, 2005–2008
Gustavo E. Velásquez, Martin Yagui, J. Peter Cegielski, Luis Asencios, Jaime Bayona, Cesar Bonilla, Hector O. Jave, Gloria Yale, Carmen Suárez, Sidney Atwood, Carmen C. Contreras, and Sonya S. Shin
Table 4
MDR TB among new smear-positive TB patients compared with regional surveillance prevalence estimates, by NTP risk group, Lima, Peru, 2005–2008*
| Risk factor | Total no. patients | No. (%) MDR TB | Odds ratio (95% CI) |
|---|---|---|---|
| New smear-positive TB patients in NTP regional surveillance data | 476 | 47 (9.9) | |
| New smear-positive TB patients in study cohort | 531 | 180 (33.9) | 4.68 (3.30–6.65) |
| HIV positive | 46 | 8 (17.4) | 1.92 (0.85– 4.36) |
| Diabetes mellitus | 107 | 18 (16.8) | 1.85 (1.02–3.33) |
| Chronic corticosteroid therapy | 4 | 0 | NA |
| Other immunosuppression | 5 | 0 | NA |
| Adverse reaction | 4 | 1 (25.0) | 3.04 (0.06–38.63) |
| Previous hospitalization within the past 2 y with duration >15 d | 5 | 2 (40.0) | 6.09 (0.49–54.15) |
| Health care worker during the past 2 y | 24 | 4 (16.7) | 1.83 (0.60–5.57) |
| Health sciences student during the past 2 y | 29 | 5 (17.2) | 1.90 (0.69–5.22) |
| Prisoner during the past 2 y | 27 | 4 (14.8) | 1.59 (0.53–4.79) |
| Adult patient with household contact risk factor(s)† | 170 | 57 (33.5) | 4.60 (2.97–7.14) |
| Pediatric patient with household contact risk factor(s)† | 13 | 7 (53.9) | 10.65 (2.90–39.71) |
| Private or self-administered treatment | 2 | 2 (100.0) | NA |
| Sputum positive during second or third month of category I treatment | 105 | 70 (66.7) | 18.26 (11.01–30.26) |
| Sputum positive during second or third month of category II treatment | 1 | 1 (100.0) | NA |
*MDR, multidrug resistant; TB, tuberculosis; NTP, National Tuberculosis Control Program; CI, confidence interval; NA, not applicable.
†Household contact risk factors are defined as household contact with a patient with known MDR TB, with a patient who showed TB treatment failure in the past 2 y, or with a patient being treated with second-line TB drugs.
